[1] JOHNSTONE T C, SUNTHARALINGAM K, LIPPARD S J. The next generation of platinum drugs: targeted Pt(Ⅱ) agents, nanoparticle delivery, and Pt(Ⅳ) prodrugs [J]. Chem Rev, 2016, 116(5):3436-3486.
[2] WANG X Y, GUO Z J. Targeting and delivery of platinum-based anticancer drugs [J]. Chem Soc Rev, 2013, 42(1):202-224.
[3] COUNIHAN J L, GROSSMAN E A, NOMURA D K. Cancer metabolism: current understanding and therapies [J]. Chem Rev, 2018, 118(14):6893-6923.
[4] KENNY R G, MARMION C J. Toward multi-targeted platinum and ruthenium drugs-a new paradigm in cancer drug treatment regimens? [J]. Chem Rev, 2019, 119(2):1058-1137.
[5] KENNY R G, CHUAH S W, CRAWFORD A, et al. Platinum(Ⅳ) prodrugs-a step closer to Ehrlich′s vision? [J]. Eur J Inorg Chem, 2017, 2017(12): 1596-1612.
[6] MA D L, SHUM T Y, ZHANG F, et al. Water soluble luminescent platinum terpyridine complexes with glycosylated acetylide and arylacetylide ligands: photoluminescent properties and cytotoxicities [J]. Chem Commun (Camb), 2005, 37:4675-4677.
[7] RAMU V, GAUTAM S, GARAI A, et al. Glucose-appended platinum(Ⅱ)-BODIPY conjugates for targeted photodynamic therapy in red light [J]. Inorg Chem, 2018, 57(4):1717-1726.
[8] BERGER I, NAZAROV A A, HARTINGER C G, et al. A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? [J]. Chem Med Chem, 2007, 2(4):505-514.
[9] MIKATA Y, SHINOHARA Y, YONEDA K, et al. Unprecedented sugar-dependent in vivo antitumor activity of carbohydrate-pendant cis-diamminedichloroplatinum(Ⅱ) complexes[J]. Bioorg Med Chem Lett, 2001, 11(23):3045-3047.
[10] YANO S, OHIC H, ASHIZAKID M, et al. Syntheses, characterization, and antitumor activities of platinum(Ⅱ) and palladium(Ⅱ) complexes with sugar-conjugated triazole ligands[J]. Chem Biodivers, 2012, 9(9):1903-1915.
[11] CHEN Y, HEEG M J, BRAUNSCHWEIGER P, et al. A carbohydrate-linked cisplatin analogue having antitumor activity[J]. Angew Chem, 1999, 111(12):1882-1884.
[12] SHI J C, TONG Q S, JIA L. et al. Carbohydrate derivative, platinum complex with anticancer effect and preparation method thereof: China, 200610172630.2[P]. 20070711.
[13] MÖKER J, THIEM J. Synthesis of novel gluco- and galacto-functionalized platinum complexes[J]. Eur J Org Chem, 2009, 2009(28):4842-4847.
[14] CUCCIOLITO M E, LITTO R D, FANIZZI F P, et al. Hydrophilic ligands derived from glucose: synthesis, characterization and in vitro cytotoxic activity on cancer cells of Pt(Ⅱ) complexes[J]. Inorg Chim Acta, 2010, 363(4):741-747.
[15] CUCCIOLITO M E, DE LUCA BOSSA F, ESPOSITO R, et al. C-Glycosylation in platinum-based agents: a viable strategy to improve cytotoxicity and selectivity[J]. Inorg Chem Front, 2018,5:2921-2933.
[16] CUCCIOLITO M E, D′AMORA A, DE FEO G, et al. Five-coordinate platinum(Ⅱ) compounds containing sugar ligands: synthesis, characterization, cytotoxic activity, and interaction with biological macromolecules[J]. Inorg Chem, 2018, 57(6):3133-3143.
[17] ANNUNZIATA A, CUCCIOLITO M E, ESPOSITO R, et al. A highly efficient and selective antitumor agent based on a glucoconjugated carbene platinum(ii) complex[J]. Dalton Trans, 2019, 48(22):7794-7800.
[18] PATRA M, AWUAH S G, LIPPARD S J. Chemical approach to positional isomers of glucose-platinum conjugates reveals specific cancer targeting through glucose-transporter-mediated uptake in vitro and in vivo[J]. Am Chem Soc,2016,138(38):12541-12551.
[19] PATRA M, JOHNSTONE T C, SUNTHARALINGAM K, et al. A potent glucose-platinum conjugate exploits glucose transporters and preferentially accumulates in cancer cells[J]. Angew Chem, 2016, 55(7):2550-2554.
[20] LIU P, LU Y, GAO X, et al. Highly water-soluble platinum(Ⅱ) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties[J]. Chem Commun (Camb), 2013, 49(24):2421-2423.
[21] GAO X, LIU S, SHI Y, et al. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(Ⅱ) complexes as new tumor targeting agents[J]. Eur J Med Chem, 2017, 125:372-384.
[22] HAN J, GAO X, LIU R, et al. Design, synthesis of novel platinum(Ⅱ) glycoconjugates, and evaluation of their antitumor effects[J]. Chem Biol Drug Des, 2016, 87(6):867-877.
[23] LI H, GAO X, LIU R, et al. Glucose conjugated platinum(Ⅱ) complex: antitumor superiority to oxaliplatin, combination effect and mechanism of action[J]. Eur J Med Chem, 2015, 101: 400-408.
[24] LIU R, FU Z, ZHAO M, et al. GLUT1-mediated selective tumor targeting with fluorine containing platinum(Ⅱ) glycoconjugates[J]. Oncotarget, 2017, 8(24):39476-39496.
[25] LIU R, LI H, GAO X, et al. Mannose-conjugated platinum complexes reveals effective tumor targeting mediated by glucose transporter 1[J]. Biochem Biophys Res Commun, 2017, 487(1):34-40.
[26] MI Q, MA Y, GAO X, et al. 2-Deoxyglucose conjugated platinum (Ⅱ) complexes for targeted therapy: design, synthesis, and antitumor activity[J]. J Biomol Struct Dyn, 2016, 34(11):2339-2350.
[27] WU M, LI H, LIU R, et al. Galactose conjugated platinum(Ⅱ) complex targeting the Warburg effect for treatment of non-small cell lung cancer and colon cancer[J]. Eur J Med Chem, 2016, 110: 32-42.
[28] LI T, GAO X, YANG L, et al. Methyl 6-amino-6-deoxy-d-pyranoside-conjugated platinum(Ⅱ) complexes for glucose transporter (GLUT)-mediated tumor targeting: synthesis, cytotoxicity, and cellular uptake mechanism[J]. Chem Med Chem, 2016,11(10):1069-1077.
[29] GABANO E, RAVERA M, OSELLA D. Pros and cons of bifunctional platinum(Ⅳ) antitumor prodrugs: two are (not always) better than one[J]. Dalton Trans, 2014, 43(26):9813-9820.
[30] WANG Q P, HUANG Z L, MA J, et al. Design, synthesis and biological evaluation of a novel series of glycosylated platinum(Ⅳ) complexes as antitumor agents[J]. Dalton Trans, 2016, 45(25):10366-10374.
[31] MA J, WANG Q, YANG X, et al. Glycosylated platinum(Ⅳ) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects[J]. Dalton Trans, 2016, 45(29):11830-11838.
[32] MA J, YANG X, HAO W, et al. Mono-functionalized glycosylated platinum(Ⅳ) complexes possessed both pH and redox dual-responsive properties: exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo[J]. Eur J Med Chem, 2017, 128: 45-55.
[33] MA J, WANG Q, HUANG Z, et al. Glycosylated platinum(Ⅳ) complexes as substrates for glucose transporters (GLUTs) and organic cation transporters (OCTs) exhibited cancer targeting and human serum albumin binding properties for drug delivery[J]. J Med Chem, 2017, 60(13):5736-5748.
[34] MA J, LIU H, XI Z, et al. Protected and de-protected platinum(Ⅳ) glycoconjugates with GLUT1 and OCT2-mediated selective cancer targeting: demonstrated enhanced transporter-mediated cytotoxic properties in vitro and in vivo[J]. Front Chem, 2018, 6: 386.
[35] WANG H F, YANG X D, ZHAO C L, et al. Glucose-conjugated platinum(Ⅳ) complexes as tumor-targeting agents: design, synthesis and biological evaluation[J]. Bioorg Med Chem, 2019, 27(8):1639-1645.
[36] HOLLIS L S, STERN E W. Cis-Diamineplatinum complexes with diphosphonates as antitumor agents: US, 90307746.9[P]. 1991-04.
[37] SACHINVALA N D, CHEN H.Novel sucrose ligands, methods for their preparation, platinum complexesderived therefrom, and methods for their usage:US, PCT/US93/06166[P]. 1993-07-29.
[38] SACHINVALA N D, CHEN H, NIEMCZURA W P, et al. Synthesis, characterization, and anticancer activities of the first platinum complexes from sucrose[J]. Med Chem, 1993, 36(12):1791-1795.